A pilot clinical study further suggests that tumor patients with ERβ >60% derive longer overall survival from gefitinib plus fulvestrant than those with lower ERβ expression (65.5 vs. 21 weeks), highlighting ERβ as a predictive marker [66]. This evidence concerns the gene ESR2 and neoplasm.